CUV.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:10):

Stats
今日成交量	45 805.00
平均成交量	139 228
市值	744.54M
EPS	$0 ( 2024-02-21 )
Last Dividend	$0.0500 ( 2023-09-05 )
Next Dividend	$0 ( N/A )
P/E	26.07
ATR14	$0.0210 (0.14%)

音量相关性

長: 0.03 (neutral)

短: -0.36 (neutral)

Signal:(70.379) Neutral

Clinuvel Pharmaceuticals 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Clinuvel Pharmaceuticals 相关性 - 货币/商品

-0.41
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.53
( weak negative )

-0.45
( neutral )

-0.56
( weak negative )

Clinuvel Pharmaceuticals 财务报表

Annual	2023
营收:	$78.32M
毛利润:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
营收:	$78.32M
毛利润:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
营收:	$65.72M
毛利润:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
营收:	$47.98M
毛利润:	$43.26M (90.16 %)
EPS:	$0.513

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0400 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.00 - Stable (0.02%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0200	2018-09-21
Last Dividend	$0.0500	2023-09-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.185	--
Avg. Dividend % Per Year	0.00%	--
Score	2.86	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.00
Div. Directional Score	7.68	--

Next Divdend (Est)
(2024-07-01)

$0.0598 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.86

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
GNG.AX	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
REH.AX	Ex Dividend Knight	2023-10-10	Semi-Annually	0.00%
BKL.AX	Ex Dividend Knight	2023-07-25	Annually	0.00%
KOV.AX	Ex Dividend Knight	2023-08-17	Semi-Annually	0.00%
SPK.AX	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
CNI.AX	Ex Dividend Knight	2023-06-29	Semi-Annually	0.00%
MTS.AX	Ex Dividend Knight	2023-07-18	Semi-Annually	0.00%
WAM.AX	Ex Dividend Knight	2023-10-17	Semi-Annually	0.00%
ECF.AX	Ex Dividend Junior	2023-06-29	Quarterly	0.00%
PBH.AX	No Dividend Player	2023-09-06	Insufficient data to determine frequency	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.70	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.336	1.500	1.588	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	-0.831	1.500	-8.87	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				5.00

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.